We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: GLP-1 RAs efficacious for weight reduction in obese, weight problems with out diabetes
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > GLP-1 RAs efficacious for weight reduction in obese, weight problems with out diabetes
GLP-1 RAs efficacious for weight reduction in obese, weight problems with out diabetes
Health

GLP-1 RAs efficacious for weight reduction in obese, weight problems with out diabetes

Last updated: January 8, 2025 8:01 am
Editorial Board Published January 8, 2025
Share
SHARE

For adults with obese or weight problems with out diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight reduction, based on a assessment revealed on-line Jan. 7 within the Annals of Inner Drugs.

Areesha Moiz, from McGill College in Montreal, and colleagues examined the efficacy and security of GLP-1 RAs and co-agonists for weight problems therapy amongst adults with out diabetes in a scientific assessment of placebo-controlled randomized managed trials (RCTs) in in any other case wholesome adults with obese or weight problems. Twenty-six RCTs, with 15,491 individuals and 12 brokers (three commercially accessible and 9 premarket), have been included.

The researchers discovered that tirzepatide (15 mg as soon as weekly), semaglutide (2.4 mg as soon as weekly), and liraglutide (3.0 mg as soon as every day) resulted in weight lack of as much as 17.8, 13.9, and 5.8% after 72, 68, and 26 weeks of remedy, respectively, in contrast with placebo. Retatrutide (12 mg as soon as weekly) resulted in weight lack of as much as 22.1% after 48 weeks; different novel single and mixture GLP-1 brokers have been additionally efficacious. Antagonistic occasions have been frequent (80 to 97% versus 63 to 100% for GLP-1 RA versus placebo); most have been gastrointestinal-related, together with nausea, vomiting, diarrhea, and constipation.

“Our results support the use of GLP-1 RAs and co-agonists for the treatment of overweight or obesity among patients without diabetes,” the authors write.

Extra info:
Areesha Moiz et al, Efficacy and Security of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Amongst Adults With out Diabetes, Annals of Inner Drugs (2025). DOI: 10.7326/ANNALS-24-01590

2025 HealthDay. All rights reserved.

Quotation:
GLP-1 RAs efficacious for weight reduction in obese, weight problems with out diabetes (2025, January 7)
retrieved 8 January 2025
from https://medicalxpress.com/information/2025-01-glp-ras-efficacious-weight-loss.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

Medical hashish program modifications drastically when including anxiousness as a qualifying situation, examine finds

Biobank information helps clarify why some people expertise extra uncomfortable side effects from antidepressants

New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels

Overview compares efficacy, security of therapies for hidradenitis suppurativa

The parable of 200 day by day meals selections: Research challenges widely-cited declare

TAGGED:DiabetesefficaciousGLP1lossObesityoverweightRAsWeight
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
U.S. Warns of Grim Toll if Putin Pursues Full Invasion of Ukraine
Politics

U.S. Warns of Grim Toll if Putin Pursues Full Invasion of Ukraine

Editorial Board February 6, 2022
In Senegal’s Former Capital, a Colonial Statue in Hiding Is No Longer Welcome
Biden Says Fighting Inflation Is ‘Top Priority’ as Prices Bite Consumers
Exploring exercise-induced arterial variations in school baseball gamers
Anti-swelling drug hinders mind most cancers immunotherapy, examine suggests

You Might Also Like

Breast most cancers: Therapy choices on foundation of biomarker-based take a look at may be dangerous
Health

Breast most cancers: Therapy choices on foundation of biomarker-based take a look at may be dangerous

July 7, 2025
AI mannequin analyzes speech to detect early neurological problems with excessive accuracy
Health

AI mannequin analyzes speech to detect early neurological problems with excessive accuracy

July 7, 2025
Youngsters below three can study new phrases even when audio system put on masks
Health

Youngsters below three can study new phrases even when audio system put on masks

July 7, 2025
Therapy timing is crucial to Prozac’s influence on temper behaviors
Health

Therapy timing is crucial to Prozac’s influence on temper behaviors

July 7, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?